VHP leader justifies murder of innocent Muslim; urges Hindus to support killers

Chikkamagaluru, Jan 19: A Chikkamagaluru court on Saturday were sentenced to death two persons convicted of rape and murder 18-year-old girl in 2016.

Pradeep M, 32, and Santhosh, 24, of Vykuntapura in Sringeri taluk raped a 18-year-old girl while she was returning home from college on Februrary 16, 2016.

The crime in which a first year B.Com student who was walking towards her home in a footway was stopped, raped and murdered by the duo. The killers then had dumped her body in a discarded well.

Wayanad, Apr 21: Panic gripped residents of Mananthavady and Mepaddi regions of the district after several cats in the region were found dead.

A group of people approached authorities after which the Animal Husbandry Department tested samples from the carcasses and found that the cat deaths were caused by Feline Parvovirus, which does not transmit to humans.

Speaking to ANI, Dr D Ramachandran, Chief Veterinary Officer, Wayanad said that Feline Parvovirus affects cats and vaccines are available to protect cats and keep the virus at bay.

"There were incidents of cat deaths in Mananthavady and Meppadi region of Wayanad district creating panic among the local residents. The officials of the Animal Husbandry department visited the spots for epidemiological investigations. The samples were collected and sent to the State Institute of Animal Diseases, which confirmed that the deaths were due to Feline Parvovirus. There is no need to worry as this virus does not spread to humans," he said.

A cat owner in Meppadi said that within a span of two-three days, over 13 cats had died in the region.

"We are afraid of these sudden cat deaths amidst coronavirus outbreak. We have informed the Health Department and Animal Husbandry department. Officials came here and collected the samples," she said.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.